Jeannine S. McCune

Jeannine S. McCune

Auto-generated profile, based on publicly available information

Jeannine S. McCune

Department of Hematologic Malignancies Translational Sciences City of Hope Duarte California USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1999 in Cancer Practice
Verified
Journal Article
Closed access
PDF file
CLCeleste Lindley
Celeste Lindley
JMJeannine S. McCune
Jeannine S. McCune
TTTracy E. Thomason
Tracy E. Thomason
DLDionne Lauder
Dionne Lauder
ASAmy Sauls
Amy Sauls
WSWilliam T. Sawyer
William T. Sawyer

1 November 2016 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JPJeanne Palmer
Jeanne Palmer
JMJeannine S. McCune
Jeannine S. McCune
MPMiguel-Angel Perales
Miguel-Angel Perales
DMDavid Marks
David Marks
JBJoseph Bubalo
Joseph Bubalo
PCPaul A. Carpenter
Paul A. Carpenter
The Practice Guidelines Committee of the American Society of Blood or Marrow Transplantation (ASBMT) sought to develop an evidence-based review about personalizing busulfan-based conditioning. The Committee sought to grade the relevant published studies (June 1, 2008 through March 31, 2016) according to criteria set forth by the Steering Committee for Evidence Based Reviews from ASBMT. Unfortunately, the published literature was too heterogeneous and lacked adequately powered and sufficiently controlled studies for this to be feasible. Despite this observation, the continued interest in this topic led the Practice Guidelines Committee to develop a list of most frequently asked questions (FAQs) regarding personalized busulfan dosing. This "Considerations" document is a list of these FAQs and their responses, addressing topics of practical relevance to hematopoietic cell transplantation clinicians.

1 February 2014 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JMJeannine S. McCune
Jeannine S. McCune
MBMeagan J. Bemer
Meagan J. Bemer
JBJeffrey S. Barrett
Jeffrey S. Barrett
KBK. Scott Baker
K. Scott Baker
AGAlan S. Gamis
Alan S. Gamis
NHNicholas H.G. Holford
Nicholas H.G. Holford
Purpose: Personalizing intravenous busulfan doses to a target plasma concentration at steady state (Css) is an essential component of hematopoietic cell transplantation (HCT). We sought to develop a population pharmacokinetic model to predict i.v. busulfan doses over a wide age spectrum (0.1–66 years) that accounts for differences in age and body size. Experimental Design: A population pharmacokinetic model based on normal fat mass and maturation based on postmenstrual age was built from 12,380 busulfan concentration time points obtained after i.v. busulfan administration in 1,610 HCT recipients. Subsequently, simulation results of the initial dose necessary to achieve a target Css with this model were compared with pediatric-only models. Results: A two-compartment model with first-order elimination best fit the data. The population busulfan clearance was 12.4 L/h for an adult male with 62 kg normal fat mass (equivalent to 70 kg total body weight). Busulfan clearance, scaled to body size—specifically normal fat mass, is predicted to be 95% of the adult clearance at 2.5 years postnatal age. With a target Css of 770 ng/mL, a higher proportion of initial doses achieved the therapeutic window with this age- and size-dependent model (72%) compared with dosing recommended by the U.S. Food and Drug Administration (57%) or the European Medicines Agency (70%). Conclusion: This is the first population pharmacokinetic model developed to predict initial i.v. busulfan doses and personalize to a target Css over a wide age spectrum, ranging from infants to adults. Clin Cancer Res; 20(3); 754–63. ©2013 AACR.

1 October 2000 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
JMJeannine S. McCune
Jeannine S. McCune
RHRoy L. Hawke
Roy L. Hawke
ELEdward L. LeCluyse
Edward L. LeCluyse
HGHeidi H. Gillenwater
Heidi H. Gillenwater
GHGeraldine Hamilton
Geraldine Hamilton
CLCeleste Lindley
Celeste Lindley
The aims of these experiments were to determine the effect of a therapeutic regimen of dexamethasone on cytochrome P4503A4 (CYP3A4) activity in healthy volunteers; and the concentration-effect relationship between dexamethasone and CYP3A4 activity in primary human hepatocyte cultures. The effect of dexamethasone (8 mg administered by mouth two times a day for 5 days) on CYP3A4 activity in 12 healthy volunteers was assessed with the erythromycin breath test and urinary ratio of dextromethorphan to 3-methoxymorphinan. Concentration-effect of dexamethasone on CYP3A4-dependent testosterone 6-beta-hydroxylation was determined in human hepatocytes treated with 2 to 250 micromol/L dexamethasone. The percent of erythromycin metabolized per hour increased from 2.20% +/- 0.60% (mean +/- SD) at baseline to 2.67% +/- 0.55% on day 5 of dexamethasone (mean increase in hepatic CYP3A4 activity 25.7% +/- 24.6%; P = .004). The mean urinary ratio of dextromethorphan to 3-methoxymorphinan was 28 (4.8 to 109) and 7 (1 to 23) at baseline and on day 5 of dexamethasone (mean decrease = 49%; P = .06). Substantial intersubject variability was observed in the extent of CYP3A4 induction. The extent of CYP3A4 induction was inversely correlated with baseline erythromycin breath test (r2 = 0.58). In hepatocytes, dexamethasone 2 to 250 micromol/L resulted in an average 1.7-fold to 6.9-fold increase in CYP3A4 activity, respectively. The extent of CYP3A4 induction with dexamethasone in hepatocyte preparations was inversely correlated with baseline activity (r2 = 0.59). These data demonstrate that dexamethasone at doses used clinically increased CYP3A4 activity with extensive intersubject variability and that the extent of CYP3A4 induction was, in part, predicted by the baseline activity of CYP3A4 in both healthy volunteers and human hepatocyte cultures.

3 February 2025 in Nature Materials
Verified
Journal Article
Closed access
PDF file
MWMinqiang Wang
Minqiang Wang
Cui YeCui Ye
Cui Ye
YYYiran Yang
Yiran Yang
DMDaniel Mukasa
Daniel Mukasa
CWCanran Wang
Canran Wang
Wei GaoWei Gao
Wei Gao

25 January 2019 in Natural Product Reports
Verified
Journal Article
Open access
PDF file
JKJoshua Kellogg
Joshua Kellogg
MPMary Paine
Mary Paine
JMJeannine S. McCune
Jeannine S. McCune
NONicholas H. Oberlies
Nicholas H. Oberlies
NCNadja B. Cech
Nadja B. Cech
Covering: up to the end of 2018 Dietary supplements, which include botanical (plant-based) natural products, constitute a multi-billion-dollar industry in the US. Regulation and quality control for this industry is an ongoing challenge. While there is general agreement that rigorous scientific studies are needed to evaluate the safety and efficacy of botanical natural products used by consumers, researchers conducting such studies face a unique set of challenges. Botanical natural products are inherently complex mixtures, with composition that differs depending on myriad factors including variability in genetics, cultivation conditions, and processing methods. Unfortunately, many studies of botanical natural products are carried out with poorly characterized study material, such that the results are irreproducible and difficult to interpret. This review provides recommended approaches for addressing the critical questions that researchers must address prior to in vitro or in vivo (including clinical) evaluation of botanical natural products. We describe selection and authentication of botanical material and identification of key biologically active compounds, and compare state-of-the-art methodologies such as untargeted metabolomics with more traditional targeted methods of characterization. The topics are chosen to be of maximal relevance to researchers, and are reviewed critically with commentary as to which approaches are most practical and useful and what common pitfalls should be avoided.